GLP-1 Treatment After the Wedding: Read the Withdrawal Studies and Plan Your Review

The wedding is over, and the next prescription refill is approaching. You may want to continue treatment, reduce its burden, discuss side effects or stop for a particular reason. Book that conversation around your health and circumstances. The end of the celebration does not answer the medication question.

What the semaglutide extension measured

The STEP 1 extension followed a subset of 327 participants after the original trial's treatment period. Participants had overweight or obesity and did not have diabetes. Semaglutide and the structured lifestyle intervention stopped at week 68; the extension followed participants for another year. [1]

The semaglutide group had lost an average of 17.3% of starting body weight during treatment. Over the following year, they regained 11.6 percentage points, leaving an average loss of 5.6% from the original baseline. That is the basis for the description of regaining about two-thirds of the earlier loss. [1]

It does not mean two-thirds of participants regained all their weight. The figures describe a group average. The extension was exploratory and involved a selected subset, and both medicine and structured lifestyle support ended. It cannot isolate every possible effect of a different stopping plan. Novo Nordisk funded the study. [1]

What the randomized tirzepatide withdrawal trial measured

SURMOUNT-4 used a different design. After 36 weeks of open-label tirzepatide, 670 participants were randomized to continue treatment or switch to placebo for 52 weeks. The randomized group had lost an average of 20.9% during the initial period. Participants did not have diabetes. [2]

From randomization, the continuing group lost another 5.5% on average, while the placebo group gained 14.0%. Those percentages use weight at randomization as the reference, rather than the original starting weight. [2]

The 14.0% figure therefore does not mean gaining back only 14% of the pounds previously lost. The time point and denominator matter when reading a headline.

The trial supports a difference between continuation and withdrawal in people who completed the initial treatment period. It does not show that everyone starting tirzepatide will have the same experience. Eli Lilly sponsored the trial. [2]

Dose reduction is a separate research question

A newer trial, SURMOUNT-MAINTAIN, was published in 2026. Its current abstract describes 378 participants randomized after a 60-week tirzepatide period to continue the maximum tolerated dose, reduce to 5 mg or switch to placebo for another 52 weeks. Rescue tirzepatide could be introduced later for substantial regain. [3]

This is a different question from stopping treatment outright, and it tested a specific transition rather than every possible taper. It should not be converted into instructions to change your own dose.

Evidence note: the publication has a linked June 2026 correction whose full text was unavailable during this review. This article therefore identifies the newer trial without reproducing its numerical outcome estimates. Ask your clinician to review the current paper and correction when considering this evidence. [3] [4]

Begin your appointment with the reason for review

Write a sentence that identifies the current problem. “My coverage ends next month” calls for a different discussion from “I have ongoing nausea,” “I am planning pregnancy,” or “I want to understand the purpose of continuing.”

Bring the exact product, formulation, dose, schedule and date of the last dose. List any interruptions and how you handled them. Include other medicines and supplements, particularly anything added during wedding preparations.

Describe benefits in terms you recognize: a health measure your clinician follows, symptoms, eating patterns, mobility or other treatment goals. Also describe unwanted effects and the time, cost or practical burden involved.

Ask what the medicine is currently treating and how success is being assessed. Avoid making the final dress measurement the main criterion for a medical decision.

Raise cost and supply concerns before the last dose

Bring the coverage notice or pharmacy information if access is changing. Identify the date the current supply will run out and the next appointment available. Ask the office which details it needs to review the options.

Do not assume that stretching intervals, splitting a presentation or using another person's supply is an acceptable transition. Ask the prescriber and pharmacist for instructions for the exact product if access is interrupted.

For any proposed alternative, ask what it treats, how it differs, how to begin it and what follow-up is required. A different brand or formulation may bring different instructions. Record the plan rather than relying on a remembered conversation.

If the office cannot complete the review before the supply ends, ask how to handle that situation. Keep a record of whom you contacted and the advice given.

Review eating, activity and symptoms together

The 2025 joint GLP-1 nutrition advisory emphasizes nutritional adequacy, management of gastrointestinal symptoms and resistance exercise as part of care. These are continuing care needs, not tasks that expire after the wedding. [5]

Describe an ordinary week now that planning events have ended. Are meals easier to arrange? Are you still struggling to eat enough? Has activity returned to its previous pattern? Which symptoms continue?

Ask for dietitian or other support if intake remains limited or your routine is difficult to sustain. A plan that depends on foods you cannot tolerate needs adjustment, regardless of what the scale shows.

The small-appetite food article and strength-planning article provide questions you can reuse after the celebration. Adapt the logistics to work, travel and home life.

If concern about eating, checking weight or body changes is consuming much of the day, say so at the review. Ask which support fits the problem and how monitoring can be made useful without becoming constant.

Bring reproductive and other treatment plans

If pregnancy is possible or planned, raise it before changing contraception or waiting for the next routine refill. The exact medicine and reason it is prescribed matter. Ask the clinician to review the current label and agree on the timing and treatment plan.

Include skin and hair prescriptions in that conversation. A medicine used for acne or shedding may need its own review. The contraception and pregnancy-planning article explains the product-specific questions.

Also mention upcoming procedures, travel or a change in the clinician responsible for care. Ask how records and prescriptions will transfer if you are moving or changing practices.

Leave with instructions for the next stage

Ask what will be monitored, by whom and when. The answer may include symptoms, nutritional intake, functional concerns or health measures relevant to your diagnosis. Request the purpose of each measurement so you know what a change would mean.

Confirm whom to contact for worsening symptoms, an access interruption or questions about a missed dose. If stopping or changing treatment is agreed, obtain the actual instructions, not just the statement that you can discuss it later.

Neither STEP 1's extension nor SURMOUNT-4 established a universal taper that prevents regain. Their results are a reason to plan follow-up, not to predict a personal outcome or assign blame.

Keep the review focused on the life you are living now. Bring the written plan back if circumstances change, so the next decision begins with current information.

Physical Book (No Download)

Bridegenic: The Glow-Up Guide for Brides on GLP-1s

$12.95 + Free Shipping

Order Now

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Talk with your prescriber, pharmacist or dermatologist about decisions for your care.